Ocular Therapeutix
- Country
- 🇺🇸United States
- Ownership
- -
- Employees
- 267
- Market Cap
- $1.4B
- Introduction
Ocular Therapeutix, Inc. is a biopharmaceutical company, which engages in the development and commercialization of therapies for diseases and conditions of the eye. Its product pipeline includes Dextenza, OTX-TP, and OTX-TIC. The company was founded by Amarpreet S. Sawhney and Farhad Khosravi on September 12, 2006 and is headquartered in Bedford, MA.
Perfluorohexyloctane Shows Unprecedented Rapid Relief for Dry Eye Disease in Phase 4 Study
A phase 4 multicenter study demonstrated that perfluorohexyloctane (MIEBO) provides significant dry eye symptom relief within just 5 minutes of application, showing nearly 50% improvement that continued to increase at subsequent timepoints.
OTX-TKI Shows Promise in Stabilizing Non-Proliferative Diabetic Retinopathy in HELIOS Trial
The HELIOS trial's 1-year results indicate that OTX-TKI, an intravitreal implant, can stabilize or improve non-proliferative diabetic retinopathy (NPDR).
Ocular Hypertension: Over 60 Companies Advance Clinical Trial Pipeline
The ocular hypertension market is expanding due to increased prevalence of conditions affecting aqueous humor outflow, leading to elevated intraocular pressure (IOP).
Ocular Therapeutix Advances AXPAXLI for Wet AMD and Plans NPDR Clinical Trial
Ocular Therapeutix's SOL-R trial for AXPAXLI in wet AMD has enrolled 311 subjects, showing significant progress in the registrational program.
Ocular Therapeutix to Present AXPAXLI Update at J.P. Morgan Healthcare Conference
Ocular Therapeutix will present its 2025 strategic outlook at the 43rd Annual J.P. Morgan Healthcare Conference on January 13, 2025.
Ocular Therapeutix Completes Enrollment in AXPAXLI Wet AMD Trial, Accelerates Second Study
Ocular Therapeutix has randomized over 300 patients in the SOL-1 Phase 3 trial for AXPAXLI, an axitinib intravitreal implant, targeting wet AMD.
OTX-TKI Implant Shows Promise in Reducing Injection Frequency for Wet AMD
A phase I study of OTX-TKI, an intravitreal implant containing axitinib, demonstrated a significant reduction in injection frequency for wet AMD patients.
Ocular Therapeutix Accelerates Axpaxli Wet AMD Trial, Anticipates Topline Data in Q4 2025
Ocular Therapeutix accelerates the SOL-1 Phase 3 trial for Axpaxli in wet AMD, expecting full enrollment by the end of 2024.
Dextenza Insert Shows Strong Efficacy in Allergic Conjunctivitis Phase 3 Trial
A Phase 3 trial of the dexamethasone intracanalicular insert (Dextenza) met its primary endpoint, significantly reducing ocular itching associated with allergic conjunctivitis.
Advancements in Ocular Therapies: Updates on Dry Eye, AMD, and Myopia Management
Aldeyra Therapeutics resubmitted its NDA for reproxalap, targeting dry eye disease symptoms with both acute and chronic activity demonstrated in trials.